Drug Discovery World

FEBRUARY 21, 2024

In October 2023, pharmaceutical company NKGen Biotech released data from its Phase I clinical trial on the use of its investigational natural killer therapy, SNK01, to treat patients with Alzheimer’s disease. RA: What are the clinical benefits of using the patient’s own cells as a treatment?

Therapies 307

Therapies Trials Treatment Disease 307

Drug Discovery World

SEPTEMBER 21, 2022

Otsuka Pharmaceutical’s Lupkynis (voclosporin) is the first oral treatment to be approved in Europe for the treatment of active lupus nephritis (LN) in adult patients. LN is a severe manifestation of systemic lupus erythematosus (SLE), a chronic and debilitating autoimmune disease that is suggested to cause irreversible nephron loss.

Treatment 130

Treatment Licensing Licensing Pharmaceuticals 130

Drug Target Review

JANUARY 15, 2024

Cancer is a disease driven by variable genetic mutations. Could you provide insights into the driving factors behind exploring novel treatments for cancer types? Based on this rationale we selected skin cancer, triple-negative breast cancer, and head and neck cancers as our initial indications for our Phase 1 trials.

Treatment 104

Treatment Immune Response Clinical Trials Therapies 104

Drug Discovery World

FEBRUARY 9, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to AstraZeneca for Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC). versus 11.5%).

Treatment 130

Treatment Clinical Research International FDA 130

Drug Discovery World

APRIL 18, 2024

First results from the EAGLE-1 Phase III trial for gepotidacin show that two oral doses of the antibiotic displayed superior success rates (92.6%) when compared to the combination treatment of ceftriaxone and oral azithromycin, which saw a 91.2% The imperative for innovative treatments has never been clearer. success rate.

Trials 130

Trials DNA Treatment Regulations 130

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

Drug Discovery World

JULY 11, 2023

We are confident that the strong collaboration of the experienced teams at Evotec and BMS will make novel innovative treatment options available to patients living with a broad range of neurodegenerative conditions.” Evotec and BMS aim to identify disease-modifying treatments for a broad range of neurodegenerative diseases.

Licensing 189

Licensing Licensing Drugs Disease 189

The Pharma Data

AUGUST 30, 2021

ALXN1840 demonstrated approximately three times greater copper mobilisation from tissues than standard-of-care treatments. Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised. Wilson disease. 1 It affects one in 30,000 live births in the US.

Disease 52

Disease Trials Therapies Treatment 52

Drug Target Review

JUNE 3, 2024

How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? Essentially, our CNPs reprogramme the immune system by restoring balance and returning the body to a homeostatic state, offering a precise approach to treating immune-mediated diseases.

Disease 48

Disease Pharmaceuticals Therapies Clinical Trials 48

Drug Discovery World

MARCH 1, 2024

Pepaxto associated with increased risk of death The FDA is alerting patients and health care professionals that a clinical trial (OCEAN, Study OP-103) evaluating Pepaxto with dexamethasone showed an increased risk of death. The FDA has now suspended enrolment in all ongoing Pepaxto clinical trials.

FDA 130

FDA Clinical Trials FDA Approval Trials 130

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). NEW YORK , Jan.

Disease 52

Disease Trials Treatment Clinical Trials 52

Drug Discovery World

APRIL 25, 2023

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for the treatment of HIV. “We In 2021 there were an estimated 1.5

Research 130

Research Clinical Trials Therapies Clinical Development 130

The Pharma Data

MAY 31, 2022

the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD). Ph1 clinical trial is to evaluate the safety, tolerability, and?preliminary?efficacy?of of BRT-DA01 in patients with Parkinson’s disease.?. preliminary?efficacy?of

Trials 52

Trials Disease Clinical Trials Engineering 52

Drug Discovery World

AUGUST 21, 2023

Semaglutide manufacturer Novo Nordisk reported earlier this month that the drug reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity, as shown in the SELECT trial. The drugs are currently approved as treatments for type 2 diabetes and weight loss.

Clinical Trials 130

Clinical Trials Trials Treatment Licensing 130

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis.

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

JANUARY 4, 2021

5, 2021 07:00 UTC. February 12, 2021. March 25, 2021. 2021 First Quarter Financial Update. April 21, 2021. 2021 Second Quarter Financial Update. July 21, 2021.

Clinical Trials 52

Clinical Trials Trials Treatment Disease 52

Drug Discovery World

SEPTEMBER 26, 2022

AstraZeneca’s Tezspire (tezepelumab) has been approved in the European Union as an add-on maintenance treatment in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product. . Tezspire (tezepelumab) US prescribing information; 2021.

Clinical Trials 130

Clinical Trials Trials Disease Production 130

Drug Discovery World

JANUARY 17, 2023

Leqembi’s prospects in the Alzheimer’s disease market remain uncertain despite its advantages over Aduhelm, says analytics company GlobalData. . Leqembi is the second anti-Aβ mAb approved by the FDA for the treatment of AD, following the FDA’s approval of Biogen’s Aduhelm (aducanumab) in 2021. .

FDA 130

FDA Clinical Trials Licensing Licensing 130

Drug Discovery World

SEPTEMBER 6, 2022

Cell and gene therapies are not only transforming the way diseases are treated but are also aiming to cure entirely new patient populations. New applications and indications are being researched daily with the hope to address a wide array of rare and chronic diseases that have long been thought incurable. billion raised.

Therapies 130

Therapies Clinical Trials Production Disease 130

The Pharma Data

DECEMBER 20, 2020

Followed by Russia , Indonesia, and Korea, the second phase of the COVID-19 clinical trial was approved in Italy on Friday, December 18, 2020. Currently, it is smoothly progressing with the approval for Phase 2 clinical trials in four countries, and it is expected to see the results sequentially starting as early as the third quarter of 2021.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

Olympian Clinical Research

SEPTEMBER 16, 2022

million Americans were living with Alzheimer’s disease in 2021, according to the Centers for Disease Control and Prevention (CDC). Alzheimer’s disease is the seventh leading cause of death in the United States and is a devastating disease that can rob people of their memories and lives.

Disease 52

Disease Clinical Trials Clinical Research Trials 52

The Pharma Data

APRIL 7, 2021

today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology (AAN) Annual Meeting, to be held virtually from April 17-22. . Key AbbVie abstracts and presentation details for the 2021 AAN Annual Meeting program are outlined below. Clinical Trials Plenary Session.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

MARCH 28, 2022

Kerendia ™ (10 mg or 20 mg), a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is approved for the treatment of chronic kidney disease and type 2 diabetes, excluding patients with end-stage renal disease or on dialysis. Finerenone is different to existing CKD in T2D treatments.

Disease 52

Disease Treatment Clinical Trials Trials 52

The Pharma Data

MAY 17, 2021

The agency noted that master protocols can save drugmakers time and money in study startup and can accelerate drug development by evaluating multiple drugs at the same time and maximizing the amount of information gained during research, compared to stand-alone trials.

FDA 52

FDA Trials Therapies Treatment 52

Drug Discovery World

JANUARY 31, 2023

Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS. Helen Knight, Director of Medicines Evaluation, NICE, said: “I am delighted that we have been able to recommend this pioneering treatment for people.

Therapies 130

Therapies Clinical Trials Treatment Trials 130

Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

The Pharma Data

JULY 29, 2021

econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Nasdaq: GILD) announced today its results of operations for the second quarter 2021. “We The series of promising pipeline updates included the data from the landmark ZUMA-7 study for the treatment of second-line large B-cell lymphoma.

Science 52

Science Production Treatment FDA 52

Drug Discovery World

APRIL 4, 2023

Orserdu (elacestrant), Stemline Therapeutics The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer was approved in the US in February. The drug was granted orphan drug designation by the FDA in May 2021.

FDA 130

FDA FDA Approval Small Molecule Therapies 130

The Pharma Data

OCTOBER 27, 2020

Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease (RPD) designations to PBKR03 for the treatment of Krabbe disease (Globoid Cell Leukodystrophy). Passage Bio expects to initiate a Phase 1/2 trial for PBKR03 in the first half of 2021. About Krabbe Disease.

Disease 40

Disease FDA Treatment Clinical Trials 40

The Pharma Data

AUGUST 7, 2021

Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells. Targeted delivery to clear glycogen in muscle cells.

FDA Approval 52

FDA Approval FDA Disease Treatment 52

The Pharma Data

JANUARY 17, 2021

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P, ” Dr.

Clinical Trials 52

Clinical Trials Treatment Trials Hospitals 52

The Pharma Data

JANUARY 12, 2021

12, 2021 — Drug maker Eli Lilly on Monday announced promising results from a small study of an experimental Alzheimer disease drug called donanemab. The two-year, phase 2 clinical trial included 272 patients with mild-to-moderate Alzheimer disease symptoms. © 2021 HealthDay. Posted: January 2021.

Disease 52

Disease Clinical Trials Drugs Trials 52

The Pharma Data

JANUARY 3, 2021

. United Kingdom Medicines and Healthcare Products Regulatory Agency authorized Clinical Trial Application. 04, 2021 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. The Company expects to enroll the first subject in the first half of 2021 and provide preliminary safety and biomarker data in the second half of 2021.

Clinical Trials 52

Clinical Trials Trials Treatment FDA 52

The Pharma Data

JULY 12, 2021

Finerenone 10 mg or 20 mg is indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

FDA Approval 52

FDA Approval Disease FDA Treatment 52

The Pharma Data

JUNE 18, 2021

1 At week 56, 29 percent of patients treated with continuous RINVOQ 15 mg achieved minimal disease activity a (MDA). 1 The full, long-term results from the Phase 3 SELECT-PsA 2 clinical trial will be presented at the EULAR 2021 Virtual Congress. Efficacy data reported based on randomized treatment. NORTH CHICAGO, Ill.

Treatment 40

Treatment Therapies Clinical Trials Disease 40

The Pharma Data

JANUARY 12, 2021

13, 2021 /PRNewswire/ — Adastra Pharmaceuticals, Inc., 13, 2021 /PRNewswire/ — Adastra Pharmaceuticals, Inc., The trial investigated the safety and efficacy of ZTR, in combination with temozolomide (TMZ), in patients with recurrent high-grade gliomas. NCI’s Principal Investigator of the 17-C-0009 trial.

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

JANUARY 12, 2021

The two-year, Phase 2 clinical trial included 272 patients with mild to moderate Alzheimer’s symptoms. The trial findings need to be replicated, Dr. Michael Weiner, a leading Alzheimer’s researcher at the University of California, San Francisco, told the Times. © 2021 HealthDay. Posted: January 2021.

Clinical Trials 52

Clinical Trials Laboratories Trials Treatment 52